BP1, a potential biomarker for breast cancer prognosis.
| Autor: | Lou Y; Department of Biochemistry & Molecular Medicine, George Washington University, Washington, DC 20037, USA., Fallah Y; Department of Oncology, Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington, DC 20057, USA., Yamane K; NantOmics, Diagnostic Center in Montgomery County, Rockville, MD 20850, USA., Berg PE; Department of Biochemistry & Molecular Medicine, George Washington University, Washington, DC 20037, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Biomarkers in medicine [Biomark Med] 2018 May; Vol. 12 (5), pp. 535-545. Date of Electronic Publication: 2018 Mar 26. |
| DOI: | 10.2217/bmm-2017-0212 |
| Abstrakt: | Homeobox genes are critical in tumor development. An isoform protein of DLX4 called BP1 is expressed in 80% of invasive ductal breast carcinomas. BP1 overexpression is implicated in an aggressive phenotype and poor prognosis. BP1 upregulation is associated with estrogen receptor negativity so those tumors do not respond to antiestrogens. Breast cancer is the second leading cause of death in women. BP1 could serve as both a novel prognostic biomarker for breast cancer and a therapeutic target. In this review, we address the role of BP1 protein in tumorigenesis of breast cancer and four other malignancies. A number of functions of BP1 in cancer are also discussed. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|